The therapeutic potential of hybrid molecules against drug-resistant Acinetobacter baumannii

被引：0
作者：
Yafei Zhuang [1 ]
Junna Liu [2 ]
Yanjing Cheng [3 ]
Fei Cai [1 ]
Zhi Xu [2 ]
机构：
[1] School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Hubei, Xianning
[2] School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Hubei, Xianning
[3] School of Pharmacy, Guizhou Medical University, Gui’an New District, Guizhou
[4] Guizhou Miaoaitang Health Management Co., Ltd., Guizhou, Guiyang
来源：
Chemical Papers | 2025年 / 79卷 / 6期
关键词：
Acinetobacter baumannii; Antibacterial; Drug resistance; Hybrid molecules;
D O I：
10.1007/s11696-025-04034-3
中图分类号：
学科分类号：
摘要：
Acinetobacter baumannii as a critical priority gram-negative opportunistic pathogen has gained notoriety in recent decades, primarily due to its propensity to cause severe nosocomial infections. Acinetobacter baumannii is characterized by increased levels of resistance toward multiple classes of first-line and last-resort antibiotics, making it a serious threat to public health worldwide. Hybrid molecules, consist of two or more different pharmacophores, are able to modulate multiple targets simultaneously. Accordingly, hybrid molecules have the potential to overcome drug resistance, enhance the activity, improve pharmacokinetic properties and reduce the toxicity, and rational design of hybrid molecules is a promising strategy to provide potential prototypes for clinical deployment in the control and eradication of infections caused by drug-resistant Acinetobacter baumannii. The purpose of the present review article is to provide an emphasis on the current scenario (2020–present) of hybrid molecules with therapeutic potential against drug-resistant Acinetobacter baumannii, to open new avenues for the exploration of novel candidates to fight against drug-resistant Acinetobacter baumannii. © The Author(s), under exclusive licence to the Institute of Chemistry, Slovak Academy of Sciences 2025.
引用
收藏
页码：3547 / 3561
页数：14
相关论文
共 51 条
  • [1] Ahmed S., Mital A., Akhir A., Saxena D., Jahan K., Dubey G., Bharatam A., Dasgupta A., Chopra S., Jain R., Pyrrole-thiazolidin-4-one analogues exhibit promising anti-tuberculosis activity, Asian J Org Chem, 13, 6, (2024)
  • [2] Akunuri R., Unnissa T., Kaul G., Akhir A., Saxena D., Wajidali M., Veerareddy V., Yaddanapudi V.M., Chopra S., Nanduri S., Synthesis and antibacterial evaluation of rhodanine and its related heterocyclic compounds against S. aureus and A. baumannii, Chem. Biodiversity, 19, (2022)
  • [3] Alkhaibari I., Raj K.C.H., Angappulige D.H., Gilmore D., Alam M.A., Novel pyrazoles as potent growth inhibitors of staphylococci, enterococci and Acinetobacter baumannii bacteria, Future Med Chem, 14, 4, pp. 233-244, (2022)
  • [4] Alkhzem A.H., Woodman T.J., Blagbrough I.S., Design and synthesis of hybrid compounds as novel drugs and medicines, RSC Adv, 12, 30, pp. 19470-19484, (2022)
  • [5] Bourgard C., Rodriguez-Hernandez D., Rudenko A., Rutgersson C., Palm M., Larsson D.G.J., Farewell A., Grotli M., Sunnerhagen P., Development of dicationic bisguanidine-arylfuran derivatives as potent agents against Gram-negative bacteria, Antibiotics, 11, (2022)
  • [6] Cotman A.E., Durcik M., Benedetto Tiz D., Fulgheri F., Secci D., Sterle M., Mozina S., Sterk G.J., Kikelj D., Discovery and hit-to-lead optimization of benzothiazole scaffold-based DNA gyrase inhibitors with potent activity against Acinetobacter baumannii and Pseudomonas aeruginosa, J Med Chem, 66, 2, pp. 1380-1425, (2023)
  • [7] D'Atanasio N., Joannon A.C., Sante L.D., Mangano G., Ombrato R., Vitiello M., Bartella C., Magaro G., Prati F., Milanese C., Vignaroli C., Giorgio P.D., Tongiani S., Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors, PLoS ONE, 15, 2, (2020)
  • [8] Delancey E., Allison D., Raj H.K.C., Gilmore D.F., Fite T., Basnakian A.G., Alam M.A., Synthesis of 4,4’-(4-formyl-1H-pyrazole-1,3-diyl) dibenzoic acid derivatives as narrow spectrum antibiotics for the potential treatment of Acinetobacter Baumannii infections, Antibiotics, 9, (2020)
  • [9] Durcik M., Cotman A.E., Toplak Z., Mozina S., Skok Z., Szili P.E., Czikkely M., Tomasic T., Masic L.P., New dual inhibitors of bacterial topoisomerases with broad-spectrum antibacterial activity and in vivo efficacy against vancomycin-intermediate Staphylococcus aureus, J Med Chem, 66, 6, pp. 3968-3994, (2023)
  • [10] El-Sayed S., Ahmed S.A., Gulia K., Lenhard J.R., Hassan A.H.E., Farahat A.A., Small molecules incorporating privileged amidine moiety as potential hits combating antibiotic-resistant bacteria, Pharmaceuticals, 16, (2023)
123456